L Bergenholm1,2, J Parkinson3, J Mettetal4, N D Evans1, M J Chappell1, T Collins4. 1. Biomedical and Biological Systems Laboratory, School of Engineering, University of Warwick, Coventry, UK. 2. Drug Metabolism and Pharmacokinetics, Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Development, AstraZeneca, Gothenburg, Sweden. 3. Early Clinical Development, Quantitative Clinical Pharmacology, Innovative Medicines and Early Development, AstraZeneca, Gothenburg, Sweden. 4. Safety and ADME Translational Sciences, Drug Safety and Metabolism, Innovative Medicines and Early Development, AstraZeneca, Cambridge, UK.
Abstract
BACKGROUND AND PURPOSE: Risk of cardiac conduction slowing (QRS/PR prolongations) is assessed prior to clinical trials using in vitro and in vivo studies. Understanding the quantitative translation of these studies to the clinical situation enables improved risk assessment in the nonclinical phase. EXPERIMENTAL APPROACH: Four compounds that prolong QRS and/or PR (AZD1305, flecainide, quinidine and verapamil) were characterized using in vitro (sodium/calcium channels), in vivo (guinea pigs/dogs) and clinical data. Concentration-matched translational relationships were developed based on in vitro and in vivo modelling, and the in vitro to clinical translation of AZD1305 was quantified using an in vitro model. KEY RESULTS: Meaningful (10%) human QRS/PR effects correlated with low levels of in vitro Nav 1.5 block (3-7%) and Cav 1.2 binding (13-21%) for all compounds. The in vitro model developed using AZD1305 successfully predicted QRS/PR effects for the remaining drugs. Meaningful QRS/PR changes in humans correlated with small effects in guinea pigs and dogs (QRS 2.3-4.6% and PR 2.3-10%), suggesting that worst-case human effects can be predicted by assuming four times greater effects at the same concentration from dog/guinea pig data. CONCLUSION AND IMPLICATIONS: Small changes in vitro and in vivo consistently translated to meaningful PR/QRS changes in humans across compounds. Assuming broad applicability of these approaches to assess cardiovascular safety risk for non-arrhythmic drugs, this study provides a means of predicting human QRS/PR effects of new drugs from effects observed in nonclinical studies.
RCT Entities:
BACKGROUND AND PURPOSE: Risk of cardiac conduction slowing (QRS/PR prolongations) is assessed prior to clinical trials using in vitro and in vivo studies. Understanding the quantitative translation of these studies to the clinical situation enables improved risk assessment in the nonclinical phase. EXPERIMENTAL APPROACH: Four compounds that prolong QRS and/or PR (AZD1305, flecainide, quinidine and verapamil) were characterized using in vitro (sodium/calcium channels), in vivo (guinea pigs/dogs) and clinical data. Concentration-matched translational relationships were developed based on in vitro and in vivo modelling, and the in vitro to clinical translation of AZD1305 was quantified using an in vitro model. KEY RESULTS: Meaningful (10%) human QRS/PR effects correlated with low levels of in vitro Nav 1.5 block (3-7%) and Cav 1.2 binding (13-21%) for all compounds. The in vitro model developed using AZD1305 successfully predicted QRS/PR effects for the remaining drugs. Meaningful QRS/PR changes in humans correlated with small effects in guinea pigs and dogs (QRS 2.3-4.6% and PR 2.3-10%), suggesting that worst-case human effects can be predicted by assuming four times greater effects at the same concentration from dog/guinea pig data. CONCLUSION AND IMPLICATIONS: Small changes in vitro and in vivo consistently translated to meaningful PR/QRS changes in humans across compounds. Assuming broad applicability of these approaches to assess cardiovascular safety risk for non-arrhythmic drugs, this study provides a means of predicting human QRS/PR effects of new drugs from effects observed in nonclinical studies.
Authors: Xueying Cao; Yan Tony Lee; Mats Holmqvist; Yingxin Lin; Yucheng Ni; Dmitri Mikhailov; Haiyan Zhang; Christopher Hogan; Liping Zhou; Qiang Lu; Mary Ellen Digan; Laszlo Urban; Gül Erdemli Journal: Assay Drug Dev Technol Date: 2010-12-06 Impact factor: 1.738
Authors: Anne S Y Chain; Vincent F S Dubois; Meindert Danhof; Miriam C J M Sturkenboom; Oscar Della Pasqua Journal: Br J Clin Pharmacol Date: 2013-11 Impact factor: 4.335
Authors: Joanna Parkinson; Sandra A G Visser; Philip Jarvis; Chris Pollard; Jean-Pierre Valentin; James W T Yates; Lorna Ewart Journal: J Pharmacol Toxicol Methods Date: 2013-04-06 Impact factor: 1.950
Authors: Stephen Ph Alexander; William A Catterall; Eamonn Kelly; Neil Marrion; John A Peters; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies Journal: Br J Pharmacol Date: 2015-12 Impact factor: 8.739
Authors: S Y A Cheung; J Parkinson; U Wählby-Hamrén; C D Dota; Å M Kragh; L Bergenholm; T Vik; T Collins; C Arfvidsson; C E Pollard; H K Tomkinson; B Hamrén Journal: J Pharmacokinet Pharmacodyn Date: 2018-05-07 Impact factor: 2.745
Authors: Lindsey Ingleby-Talecki; Sven C van Dijkman; Sean P Oosterholt; Oscar Della Pasqua; Christina Winter; Marianne Cunnington; Linda Rebar; Sergio Forero-Schwanhaeuser; Vickas Patel; James A Cooper; Anthony Bahinski; Khuram W Chaudhary Journal: Clin Transl Sci Date: 2022-05-31 Impact factor: 4.438